I-Corps: Prognostic test for dairy heifer selection

I-Corps:奶牛选择的预后测试

基本信息

  • 批准号:
    2150637
  • 负责人:
  • 金额:
    $ 5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Standard Grant
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-01-15 至 2022-12-31
  • 项目状态:
    已结题

项目摘要

The broader impact/commercial potential of this I-Corps project is to develop an assay to identify calves that will not survive to 2 years of age or will be low milk producers. The goal of the proposed technology is to reduce the number of calves that must be raised by dairies as replacements so dairies may focus their resources on raising healthy, efficient, productive calves and reduce costs, feed waste, and methane and manure production. During the first 24 months of age, heifer death loss and culling can be as high as 20% resulting in a loss of $1800-$2400 per heifer. Currently, dairies are faced with raising these heifers to a productive age (2 years old) to determine which heifers to keep and which to cull when they only need to keep 50% as replacements. This adds approximately $900,000 in costs per year to feed and care for heifers that should have been sold and raised for beef at less than 1 week of age, making heifer raising the second largest cost for a dairy. In addition, the proposed technology also may be used to enable the development of other products that promote energy efficiency, milk production and health such as cardiolipin, prebiotics, probiotics, supra levels of vitamins as well as the development of novel therapies for diseases such as ketosis, fatty liver, obesity, and hypocalcaemia.This I-Corps project is based on the development of a prognostic assay of mitochondrial function to identify calves that will not survive to 2 years of age or will be low milk producers. Mitochondria are cellular energy generators and play a key role in metabolic flexibility - the ability of mitochondria to respond to physiological changes such as immune challenge, energy restriction, lactation, and gestation. Mitochondria have their own genome and are maternally inherited, however, current genetic tests do not include their impact on milk production or longevity. The proposed prognostic assay is based on measuring mitochondrial activity and includes distinct relationships between age, level of milk production, and specific mitochondrial enzyme activities within the electron transport chain. The proposed assay has been shown to predict death and culling based on data from calves tested at 3-5 days of age and followed through to their second lactation. This suggests that the assay results may predict survivability and could be used to identify potential interventions that support mitochondrial function resulting in improved immune function and milk production.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
该I-Corps项目更广泛的影响/商业潜力是开发一种测定方法,以识别不能存活至2岁或产奶量低的小牛。 拟议技术的目标是减少奶牛场必须饲养的小牛数量作为替代品,以便奶牛场可以将其资源集中在饲养健康,高效,多产的小牛上,并减少成本,饲料浪费以及甲烷和粪便生产。在头24个月的年龄,小母牛死亡损失和淘汰可高达20%,导致每头小母牛损失1800 - 2400美元。 目前,奶牛场面临着提高这些小母牛到生产年龄(2岁),以确定哪些小母牛保持和淘汰时,他们只需要保持50%作为替代品。这增加了每年约90万美元的成本,用于喂养和照顾本应在不到1周龄时出售和饲养的小母牛,使小母牛饲养成为奶牛场的第二大成本。此外,所提出的技术还可用于开发促进能量效率、产奶量和健康的其他产品,例如心磷脂、益生元、益生菌、超水平维生素,以及开发用于疾病的新疗法,例如酮症、脂肪肝、肥胖症、还有低钙血症这我... Corps项目是基于线粒体功能的预后分析的发展,以确定小牛将无法存活到2岁或将是低牛奶生产商线粒体是细胞能量产生器,在代谢灵活性中发挥关键作用-线粒体响应生理变化的能力,如免疫挑战,能量限制,哺乳和妊娠。线粒体有自己的基因组,是母系遗传的,然而,目前的基因测试不包括它们对牛奶产量或寿命的影响。所提出的预后分析是基于测量线粒体活性,包括年龄,产奶水平,和特定的线粒体酶活性的电子传递链之间的独特关系。已证明,拟议的测定方法可以根据3-5日龄小牛的测试数据预测死亡和扑杀,并一直持续到第二次哺乳期。这表明,检测结果可以预测生存能力,并可用于确定潜在的干预措施,支持线粒体功能,从而改善免疫功能和牛奶production.This奖项反映了NSF的法定使命,并已被认为是值得的支持,通过评估使用基金会的智力价值和更广泛的影响审查标准。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heidi Rossow其他文献

Heidi Rossow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Validation and Early Commercialization of the ENVISAGE Assay, a Prognostic Test for Barrett's Esophagus
ENVISAGE 检测(Barrett 食管的预后检测)的验证和早期商业化
  • 批准号:
    10761328
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Communicating the Gist of Prognosis: An intervention to improve prognostic understanding in advanced lymphoma
传达预后要点:提高对晚期淋巴瘤预后了解的干预措施
  • 批准号:
    10526566
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
Collaborative Research: Microengineered Tumor-Mimetic Collagen Landscapes to Test the Role of Prognostic Structural Cues on Cell Migration Through the Extracellular Matrix
合作研究:微工程模拟肿瘤胶原蛋白景观,以测试预后结构线索对细胞通过细胞外基质迁移的作用
  • 批准号:
    2150799
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
Menstrual Cycle-Related Symptom Variability as a Prognostic Indicator in Lymphangioleiomyomatosis
月经周期相关症状变异性作为淋巴管平滑肌瘤病的预后指标
  • 批准号:
    10513485
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
Screening ADNI patient cohorts to identify a sub-population that are AD early progressors in validating the prognostic ability of the Alzosure Predict blood test, 6 years in advance of current methods
筛选 ADNI 患者队列,识别 AD 早期进展者亚群,验证 Alzosure Predict 血液检测的预后能力,比现有方法提前 6 年
  • 批准号:
    10688164
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
Collaborative Research: Microengineered Tumor-Mimetic Collagen Landscapes to Test the Role of Prognostic Structural Cues on Cell Migration Through the Extracellular Matrix
合作研究:微工程模拟肿瘤胶原蛋白景观,以测试预后结构线索对细胞通过细胞外基质迁移的作用
  • 批准号:
    2150798
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
Prognostic and Predictive Digital Tissue Image Assay for Prostate Cancer
前列腺癌的预后和预测数字组织图像分析
  • 批准号:
    10697304
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
IMPROVING PROGNOSTIC COMMUNICATION IN PEDIATRIC CANCER
改善儿科癌症的预后沟通
  • 批准号:
    10524641
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
Communicating the Gist of Prognosis: An intervention to improve prognostic understanding in advanced lymphoma
传达预后要点:提高对晚期淋巴瘤预后了解的干预措施
  • 批准号:
    10710023
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
Screening ADNI patient cohorts to identify a sub-population that are AD early progressors in validating the prognostic ability of the Alzosure Predict blood test, 6 years in advance of current methods
筛选 ADNI 患者队列,识别 AD 早期进展者亚群,验证 Alzosure Predict 血液检测的预后能力,比现有方法提前 6 年
  • 批准号:
    10483271
  • 财政年份:
    2022
  • 资助金额:
    $ 5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了